HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators.

Abstract
The arylmethylaminopropanediols (AMAPs) are a new class of DNA intercalators. 773U82.HCl is the second of these compounds to enter clinical trial. Significant antitumor activity for 773U82.HCl was documented in a variety of murine and human tumor models. This phase I study examined a 1-, 2- and 6-hour infusion given every 28 days. Thirty-six patients received 58 courses of drug at doses ranging from 15 mg/m2 to 980 mg/m2. The dose-limiting toxicity of 773U82.HCl was hemolysis noted at 980 mg/m2. Change in color of the plasma and decreases in haptoglobin were correlated with drug concentrations of the infusate greater than or equal to 3 mg/ml. Clinically significant changes in hemoglobin levels requiring blood transfusions did not occur. Neurologic toxicity occurred at 720 mg/m2 with the most severe neurologic toxicity occurring in a patient with the highest peak plasma concentration (4.1 micrograms/ml). With an increase in duration of the infusion and amount of fluid administered, the neurologic toxicity resolved. Other toxicities included mild nausea and vomiting and a dose-related phlebitis. Pharmacokinetic studies were completed in 22 patients. The mean terminal t1/2 beta was 4.4 h with a mean apparent volume of distribution at steady state (Vdss) of 314 l/m2. The mean total body clearance was 72 l/h/m2. Peak plasma levels ranged from 0.04 to 4.14 micrograms/ml. Further studies with 773U82.HCl on this schedule at the doses studied are not recommended. Hematologic monitoring for evidence of intravascular hemolysis should be included in future studies with 773U82.HCl.
AuthorsK A Havlin, J G Kuhn, J B Craig, G R Weiss, J Koeller, J N Turner, J S Luther, G Clark, K W Bair, W Wargin
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 2 Issue 4 Pg. 357-63 (Aug 1991) ISSN: 0959-4973 [Print] England
PMID1797191 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Fluorenes
  • Intercalating Agents
  • Propylene Glycols
  • 1,3-propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-
Topics
  • Adult
  • Aged
  • Drug Evaluation
  • Female
  • Fluorenes (pharmacokinetics, therapeutic use, toxicity)
  • Hemolysis (drug effects)
  • Humans
  • Intercalating Agents (pharmacokinetics, therapeutic use, toxicity)
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Neoplasms (drug therapy)
  • Nervous System Diseases (chemically induced)
  • Phlebitis (chemically induced)
  • Propylene Glycols (pharmacokinetics, therapeutic use, toxicity)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: